Hydroxychloroquine reduces low-density lipoprotein cholesterol levels in systemic lupus erythematosus: a longitudinal evaluation of the lipid-lowering effect

Abstract

The influence of antimalarials on lipids in systemic lupus erythematosus (SLE) has been identified in several studies but not in many prospective cohorts. The aim of this study was to longitudinally determine the effect of antimalarials on the lipoprotein profile in SLE. Patients and methods: Fasting total cholesterol (TC), triglycerides (TG), high-density lipoprotein (HDL) and low-density lipoprotein cholesterol (LDL) plasma levels were determined at entry and after 3 months of hydroxychloroquine (HCQ) treatment in a longitudinal evaluation of 24 patients with SLE. Results: a significant decrease in TC (198 ± 33.7 vs. 183 ± 30.3 mg/dl, p = 0.023) and LDL levels (117 ± 31.3 vs. 101 ± 26.2 mg/dl, p = 0.023) were detected after the 3 months of HCQ therapy. The reduction of 7.6% in TC (p = 0.055) and 13.7% in LDL levels (p = 0.036) determined a significant decrease in the frequency of dyslipidemia (26% vs. 12.5%, p = 0.013) after HCQ therapy. Conclusion: This longitudinal study demonstrated the beneficial effect of antimalarials on lipids in SLE since this therapy induced a reduction of atherogenic lipoproteins.

Keywords

systemic lupus erythematosus lipoprotein antimalarial hydroxychloroquine dyslipidemia therapy

Get full access to this article

View all access options for this article.

References

Bruce

. “Not only…but also”: factors that contribute to accelerated atherosclerosis and premature coronary heart disease in systemic lupus erythematosus. Rheumatology (Oxford) 2005; 44: 1492–1502.

Bessant

Duncan

Ambler

. Risk factors for cardiovascular disease in patients with systemic lupus erythematosus: a case-control study. Arthritis Rheum 2006; 55: 892–899.

Borba

Carvalho

Bonfá

. Mechanisms of dyslipoproteinemias in systemic lupus erythematosus. Clin Dev Immunol 2006; 13: 203–208.

De Carvalho

Bonfá

Borba

. Systemic lupus erythematosus and “lupus dyslipoproteinemia”. Autoimmun Rev 2008; 7: 246–250.

Sarkissian

Beyenne

Feldman

Adeli

Silverman

. The complex nature of the interaction between disease activity and therapy on the lipid profile in patients with pediatric systemic lupus erythematosus. Arthritis Rheum 2006; 54: 1283–1290.

Borba

Bonfá

. Dyslipoproteinemias in systemic lupus erythematosus: influence of disease, activity and anticardiolipin antibodies. Lupus 1997; 6: 533–539.

Ilowite

Samuel

Ginzler

Jacobson

. Dyslipoproteinemia in pediatric systemic erythematosus. Arthritis Rheum 1988; 31: 859–863.

Ruiz-Irastorza

Ramos-Casals

Brito-Zeron

Khamashta

. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis 2010; 69: 20–28.

Shinjo

Bonfá

Wojdyla

. Antimalarial treatment may have a time-dependent effect on lupus survival: data from a multinational Latin American inception cohort. Arthritis Rheum 2010; 62: 855–862.

10.

Ruiz-Irastorza

Khamashta

. Hydroxychloroquine: the cornerstone of lupus therapy. Lupus 2008; 17: 271–273.

11.

Sachet

Borba

Bonfá

Vinagre

Silva

Maranhão

. Chloroquine increases low-density lipoprotein removal from plasma in systemic lupus patients. Lupus 2007; 16: 273–278.

12.

Borba

Bonfá

. Longterm beneficial effect of chloroquine diphosphate on lipoprotein profile in lupus patients with and without steroid therapy. J Rheumatol 2001; 28: 780–785.

13.

Hodis

Quismorio

Wickham

Blankenhorn

. The lipid, lipoprotein, and apolipoprotein effects of hydroxychloroquine in patients with systemic lupus erythematosus. J Rheumatol 1993; 20: 661–665.

14.

Rahman

Gladman

Urowitz

Yuen

Hallett

Bruce

. The cholesterol lowering effect of antimalarial drugs is enhanced in patients with lupus taking corticosteroid drugs. J Rheumatol 1999; 26: 325–330.

15.

Petri

Lakatta

Magder

Goldman

. Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: a longitudinal data analysis. Am J Med 1994; 96: 254–259.

16.

Kavanaugh

Adams-Huet

Jain

Denke

McFarlin

. Hydroxychloroquine Effects on Lipoprotein Profiles (the HELP trial): A double-blind, randomized, placebo-controlled, pilot study in patients with systemic lupus erythematosus. J Clin Rheumatol 1997; 3: 3–8.

17.

Tan

Cohen

Fries

. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271–1277.

18.

Bombardier

Gladman

Urowitz

Caron

Chang

. Derivation of the SLEDAI: a disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992; 35: 630–640.

19.

Friedewald

Levy

Fredrickson

. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499–502.

20.

Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001; 285: 2486–2497.

21.

Brunzell

Albers

Haas

Goldberg

Agadoa

Sherrard

. Prevalence of serum lipid abnormalities in chronic hemodialysis. Metabolism 1977; 26: 903–910.

22.

Attman

Alaupovic

. Lipid and apolipoprotein profiles of uremic dyslipoproteinemia. Relation to renal function and dialysis. Nephron 1991; 57: 401–410.

23.

Appel

Blum

Chien

Kunis

Appel

. The hyperlipidemia of the nephrotic syndrome. Relation to plasma albumin concentration, oncotic pressure and viscosity. N Engl J Med 1985; 312: 1544–1548.

24.

Thompson

Soutar

Spengel

Jadhav

Gavigan

SJP

Myant

. Defects of receptor-mediated low density lipoprotein catabolism in homozygous familial hypercholesterolemia and hypothyroidism. Proc Soc Natl Acad Sci U S A 1981; 78: 2591–2595.

25.

Brown

. Lipoprotein disorders in diabetes mellitus. Med Clin North Am 1994; 78: 143–161.

26.

Henkin

Como

Oberman

. Secondary dyslipidemia. Inadvertent effects of drugs in clinical practice. JAMA 1992; 267: 961–268.

27.

Ettinger

Goldberg

Applebaum-Bowden

Hazzard

. Dyslipoproteinemia in systemic lupus erythematosus: Effect of corticosteroids. Am J Med 1987; 83: 503–508.

28.

Wallace

Metzger

Steicher

Turnbull

Kern

. Cholesterol-lowering effect of hydroxychloroquine in patients with rheumatic disease: reversal of deleterious effects of steroids on lipids. Am J Med 1990; 89: 322–326.

29.

Tam

Lam

Tomlinson

. Hydroxychloroquine has no significant effect on lipids and apolipoproteins in Chinese systemic lupus erythematosus patients with mild or inactive disease. Lupus 2000; 9: 413–416.

30.

Tam

Gladman

Hallett

Rahman

Urowitz

. Effect of antimalarial agents on the fasting lipid profile in systemic lupus erythematosus. J Rheumatol 2000; 27: 2142–2145.

31.

Petri

Spence

Bone

Hochberg

. Coronary artery disease risk factors in the Johns Hopkins Lupus Cohort: prevalence, recognition by patients, and preventive practices. Medicine 1992; 71: 291–302.

32.

Bruce

Urowitz

Gladman

Hallett

. Natural history of hypercholesterolemia in systemic lupus erythematosus. J Rheumatol 1999; 26: 2137–2143.

33.

Svenungsson

Jensen-Urstad

Heimburger

. Risk factors for cardiovascular disease in systemic lupus erythematosus. Circulation 2001; 104: 1887–1893.

34.

Powrie

Shojaee-Moradie

Watts

Smith

Sönksen

Jones

. Effects of chloroquine on the dyslipidemia of non-insulin-dependent diabetes mellitus. Metabolism 1993; 42: 415–419.

35.

Gerstein

Thorpe

Taylor

Haynes

. The effectiveness of hydroxychloroquine in patients with type 2 diabetes mellitus who are refractory to sulfonylureas – a randomized trial. Diabetes Res Clin Pract 2002; 55: 209–219.